Response Genetics' Q4 Revenues Increase 134 Percent on PGx Test Sales | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Genetics has reported a 134 percent increase in its fourth-quarter revenues, driven by sales of its ResponseDx line of pharmacogenomic tests.

The Los Angeles-based firm brought in total revenues of $3.4 million for the three-month period ended Dec. 31 compared to $1.4 million for the fourth quarter of 2008. The company cited a ramp up in sales of its ResponseDx tests, with revenues growing 81 percent compared to the third quarter of 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.